Trials / Recruiting
RecruitingNCT06165380
Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
A Prospective, Multicenter, Phase II Study on the Efficacy and Safety of Cardenilimab Combined With Chemotherapy in the Conversion Therapy of Locally Advanced Esophageal Squamous Cell Carcinoma.
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (estimated)
- Sponsor
- Li Zhang · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this trial is to test the efficacy and safety of cardenilimab combined with chemotherapy in the conversion therapy of locally advanced unresectable esophageal squamous cell carcinoma. type of study: clinical trial
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cardenilimab Combined With Chemotherapy | Cardenilimab Combined With Chemotherapy |
Timeline
- Start date
- 2023-10-23
- Primary completion
- 2025-08-31
- Completion
- 2025-12-31
- First posted
- 2023-12-11
- Last updated
- 2025-06-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06165380. Inclusion in this directory is not an endorsement.